Sanara Medtech Inc
NASDAQ:SMTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (16.9), the stock would be worth $17.25 (13% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 19.3 | $19.73 |
0%
|
| 3-Year Average | 16.9 | $17.25 |
-13%
|
| Industry Average | 21.8 | $22.32 |
+13%
|
| Country Average | 21.9 | $22.38 |
+13%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Sanara Medtech Inc
NASDAQ:SMTI
|
176.5m USD | 19.3 | -4.7 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY | 48.7 | 37.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 26.3 | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 18 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.8B USD | 26 | 31.1 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.8B USD | -25.4 | -16 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 12.6 | 31.1 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 33.7 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 10.3 | 21.9 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | -115.1 | -36.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Sanara Medtech Inc
Glance View
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
